Literature DB >> 9607865

Serogroup B, electrophoretic type 15 Neisseria meningitidis in Canada.

D A Kertesz1, M B Coulthart, J A Ryan, W M Johnson, F E Ashton.   

Abstract

Invasive meningococcal disease is nationally reportable in Canada. In recent years, a serogroup C genotype, designated electrophoretic type 15 (ET15), has been the most frequently isolated meningococcal genotype in Canada and has caused epidemics across the country. Between August 1993 and September 1995, there were 9 cases of invasive meningococcal disease caused by a variant of this genotype, expressing group B capsular polysaccharide. The appearance of serogroup B:ET15 was related temporally and geographically to mass immunization campaigns designed to control serogroup C meningococcal disease in Canada. Since there is no vaccine available to control serogroup B meningococcal disease, the appearance of this variant may have public-health significance if it demonstrates the same epidemic potential as its serogroup C counterpart.

Entities:  

Mesh:

Year:  1998        PMID: 9607865     DOI: 10.1086/517439

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  14 in total

1.  First report of capsule replacement among electrophoretic type 37 Neisseria meningitidis strains in Italy.

Authors:  Paola Stefanelli; Cecilia Fazio; Arianna Neri; Tonino Sofia; Paola Mastrantonio
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

2.  Genetic and antigenic analysis of invasive serogroup C Neisseria meningitidis in Canada: A decrease in the electrophoretic type (ET)-15 clonal type and an increase in the proportion of isolates belonging to the ET-37 (but not ET-15) clonal type during the period from 2002 to 2009.

Authors:  Jianwei Zhou; Frances Jamieson; Sharon Dolman; Linda Mn Hoang; Prasad Rawte; Raymond Sw Tsang
Journal:  Can J Infect Dis Med Microbiol       Date:  2012       Impact factor: 2.471

3.  Evidence for capsule switching between carried and disease-causing Neisseria meningitidis strains.

Authors:  Amanda J Beddek; Ming-Shi Li; J Simon Kroll; T William Jordan; Diana R Martin
Journal:  Infect Immun       Date:  2009-05-18       Impact factor: 3.441

Review 4.  Prospects for vaccine prevention of meningococcal infection.

Authors:  Lee H Harrison
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

Review 5.  Regulation of capsule in Neisseria meningitidis.

Authors:  Yih-Ling Tzeng; Jennifer Thomas; David S Stephens
Journal:  Crit Rev Microbiol       Date:  2015-06-19       Impact factor: 7.624

Review 6.  Update on meningococcal disease with emphasis on pathogenesis and clinical management.

Authors:  M van Deuren; P Brandtzaeg; J W van der Meer
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

Review 7.  Epidemiological profile of meningococcal disease in the United States.

Authors:  Lee H Harrison
Journal:  Clin Infect Dis       Date:  2010-03-01       Impact factor: 9.079

8.  Invasive meningococcal disease in Scotland, 1994 to 1999, with emphasis on group B meningococcal disease.

Authors:  Moe H Kyaw; Stuart C Clarke; Peter Christie; Ian G Jones; Harry Campbell
Journal:  J Clin Microbiol       Date:  2002-05       Impact factor: 5.948

9.  The capsule polymerase CslB of Neisseria meningitidis serogroup L catalyzes the synthesis of a complex trimeric repeating unit comprising glycosidic and phosphodiester linkages.

Authors:  Christa Litschko; Maria Rosaria Romano; Vittoria Pinto; Heike Claus; Ulrich Vogel; Francesco Berti; Rita Gerardy-Schahn; Timm Fiebig
Journal:  J Biol Chem       Date:  2015-08-18       Impact factor: 5.157

10.  Capsule switching among C:2b:P1.2,5 meningococcal epidemic strains after mass immunization campaign, Spain.

Authors:  Belén Alcalá; Luisa Arreaza; Celia Salcedo; María J Uría; Laura De La Fuente; Julio A Vázquez
Journal:  Emerg Infect Dis       Date:  2002-12       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.